STOCK TITAN

[Form 4] Progyny, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4

Progyny, Inc. director and Executive Chairman David J. Schlanger reported a sale of 1,893 shares of Progyny common stock on 10/01/2025 at a price of $21.52 per share. After the transaction, the filing shows he beneficially owns 220,419 shares, held directly. The filing states the shares sold were withheld to cover taxes upon the vesting of restricted stock units granted to the reporting person. The Form 4 was signed by an attorney-in-fact on 10/02/2025.

Progyny, Inc. direttore e presidente esecutivo David J. Schlanger ha riportato una vendita di 1,893 azioni ordinarie di Progyny in data 10/01/2025 a un prezzo di $21.52 per azione. Dopo la transazione, la dichiarazione mostra che detiene 220,419 azioni, detenute direttamente. La dichiarazione afferma che le azioni vendute sono state trattenute per coprire le tasse al vesting delle unità di azioni vincolate concesse alla persona che presenta la dichiarazione. Il Form 4 è stato firmato da un procuratore ad litem il 10/02/2025.

Progyny, Inc. director y presidente ejecutivo David J. Schlanger reportó la venta de 1,893 acciones comunes de Progyny el 01/10/2025 a un precio de $21.52 por acción. Después de la operación, la presentación muestra que posee beneficiosamente 220,419 acciones, mantenidas directamente. La presentación indica que las acciones vendidas fueron retenidas para cubrir impuestos al vesting de unidades de acciones restringidas concedidas a la persona que presenta el informe. El Formulario 4 fue firmado por un apoderado el 02/10/2025.

Progyny, Inc. 이사이자 수석 실행 의장(Executive Chairman)David J. Schlanger1,893주를 2025-10-01에 매도했고 주당 가격은 21.52달러였습니다. 거래 후 신고서에 따르면 그는 220,419주를 직접 보유하고 있습니다. 신고서는 매도된 주식이 제한 주식 단위의 vesting 시 발생하는 세금을 충당하기 위해 보유되었다고 명시합니다. Form 4는 2025-10-02에 대리인에 의해 서명되었습니다.

Progyny, Inc. directeur et président exécutif David J. Schlanger a déclaré une vente de 1 893 actions ordinaires de Progyny le 01/10/2025 à un prix de 21,52 $ par action. Après la transaction, le dépôt indique qu’il possède avantageusement 220 419 actions, directement détenues. Le dépôt indique que les actions vendues ont été retenues pour couvrir les impôts lors du vesting des unités d’actions restreintes accordées à la personne déclarant. Le Formulaire 4 a été signé par un mandataire le 02/10/2025.

Progyny, Inc. Direktor und geschäftsführender Vorsitzender David J. Schlanger meldete einen Verkauf von 1.893 Aktien der Progyny Stammaktien am 01.10.2025 zu einem Preis von 21,52 $ pro Aktie. Nach der Transaktion zeigt die Einreichung, dass er vorteilhaft 220.419 Aktien hält, direkt gehalten. Die Einreichung besagt, dass die verkauften Aktien zurückgehalten wurden, um Steuern bei der Vesting der restricted stock units zu decken, die dem meldenden Faktor gewährt wurden. Das Formular 4 wurde am 02.10.2025 von einem Bevollmächtigten unterschrieben.

Progyny, Inc. مدير و رئيس تنفيذي للمجلس David J. Schlanger أبلغ عن بيع 1,893 سهماً من أسهم Progyny العادية في 01/10/2025 بسعر $21.52 للسهم الواحد. بعد الصفقة، تُظهر الإيداع أنه يمتلك بصورة فاعلة 220,419 سهماً، مملوكة مباشرة. تنص الإيداع على أن الأسهم المباعة قد تم حجزها لتغطية الضرائب عند استحقاق وحدات الأسهم المقيدة الممنوحة للمبلغ عنه. تم توقيع النموذج 4 من قبل وكيل في 02/10/2025.

Progyny, Inc. 董事兼执行主席 David J. Schlanger 报告在 2025/10/01 以每股 $21.52 的价格出售了 1,893 股 Progyny 普通股。交易后,申报显示他直接持有的受益性股票为 220,419 股。申报称所售股份是为了覆盖授予申报人之受限股票单位(RSU)归属时的税费而扣留。该 Form 4 由一名代理人在 2025/10/02 签署。

Positive
  • 220,419 shares remain beneficially owned by the reporting person after the transaction
  • Sale was for tax withholding related to vested restricted stock units rather than an open-market disposition
Negative
  • Disposition of 1,893 shares at $21.52 reduced the reporting person's direct holdings
  • Form shows insider has executed a share sale within the reporting period

Insights

Insider tax-withholding sale; large residual ownership remains.

The Form 4 discloses a 10/01/2025 sale of 1,893 shares at $21.52, which the filer explains were withheld to satisfy tax obligations on vested RSUs.

The reporting person continues to beneficially own 220,419 shares directly, indicating sustained economic interest despite the withholding-based sale. The signature block shows the form was executed by an attorney-in-fact on 10/02/2025.

Progyny, Inc. direttore e presidente esecutivo David J. Schlanger ha riportato una vendita di 1,893 azioni ordinarie di Progyny in data 10/01/2025 a un prezzo di $21.52 per azione. Dopo la transazione, la dichiarazione mostra che detiene 220,419 azioni, detenute direttamente. La dichiarazione afferma che le azioni vendute sono state trattenute per coprire le tasse al vesting delle unità di azioni vincolate concesse alla persona che presenta la dichiarazione. Il Form 4 è stato firmato da un procuratore ad litem il 10/02/2025.

Progyny, Inc. director y presidente ejecutivo David J. Schlanger reportó la venta de 1,893 acciones comunes de Progyny el 01/10/2025 a un precio de $21.52 por acción. Después de la operación, la presentación muestra que posee beneficiosamente 220,419 acciones, mantenidas directamente. La presentación indica que las acciones vendidas fueron retenidas para cubrir impuestos al vesting de unidades de acciones restringidas concedidas a la persona que presenta el informe. El Formulario 4 fue firmado por un apoderado el 02/10/2025.

Progyny, Inc. 이사이자 수석 실행 의장(Executive Chairman)David J. Schlanger1,893주를 2025-10-01에 매도했고 주당 가격은 21.52달러였습니다. 거래 후 신고서에 따르면 그는 220,419주를 직접 보유하고 있습니다. 신고서는 매도된 주식이 제한 주식 단위의 vesting 시 발생하는 세금을 충당하기 위해 보유되었다고 명시합니다. Form 4는 2025-10-02에 대리인에 의해 서명되었습니다.

Progyny, Inc. directeur et président exécutif David J. Schlanger a déclaré une vente de 1 893 actions ordinaires de Progyny le 01/10/2025 à un prix de 21,52 $ par action. Après la transaction, le dépôt indique qu’il possède avantageusement 220 419 actions, directement détenues. Le dépôt indique que les actions vendues ont été retenues pour couvrir les impôts lors du vesting des unités d’actions restreintes accordées à la personne déclarant. Le Formulaire 4 a été signé par un mandataire le 02/10/2025.

Progyny, Inc. Direktor und geschäftsführender Vorsitzender David J. Schlanger meldete einen Verkauf von 1.893 Aktien der Progyny Stammaktien am 01.10.2025 zu einem Preis von 21,52 $ pro Aktie. Nach der Transaktion zeigt die Einreichung, dass er vorteilhaft 220.419 Aktien hält, direkt gehalten. Die Einreichung besagt, dass die verkauften Aktien zurückgehalten wurden, um Steuern bei der Vesting der restricted stock units zu decken, die dem meldenden Faktor gewährt wurden. Das Formular 4 wurde am 02.10.2025 von einem Bevollmächtigten unterschrieben.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Schlanger David J

(Last) (First) (Middle)
C/O PROGYNY, INC.
1359 BROADWAY, 2ND FL

(Street)
NEW YORK NY 10018

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Progyny, Inc. [ PGNY ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Executive Chairman
3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/01/2025 F(1) 1,893 D $21.52 220,419 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Shares withheld for payment of withholding taxes upon the vesting of restricted stock units granted to the Reporting Person.
Remarks:
/s/ Mark Livingston, Attorney-in-Fact 10/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Progyny (PGNY) Form 4 report?

The Form 4 reports that director and Executive Chairman David J. Schlanger sold 1,893 shares on 10/01/2025 at $21.52 per share.

Why were the 1,893 shares sold according to the filing?

The filing states the shares were withheld to pay withholding taxes upon the vesting of restricted stock units granted to the reporting person.

How many shares does the reporting person own after the transaction?

After the reported transaction the reporting person beneficially owns 220,419 shares, reported as direct ownership.

When was the Form 4 signed and filed?

The signature block shows the form was signed by an attorney-in-fact on 10/02/2025 and the transaction date is 10/01/2025.

What is the reporting person’s relationship to Progyny?

The filer is identified as a Director and the Executive Chairman of Progyny, Inc.
Progyny, Inc.

NASDAQ:PGNY

PGNY Rankings

PGNY Latest News

PGNY Latest SEC Filings

PGNY Stock Data

1.77B
79.47M
7.58%
103.87%
8.08%
Healthcare Plans
Services-misc Health & Allied Services, Nec
Link
United States
NEW YORK